Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase 48,000 shares of the Company's common stock. The shares underlying each employee's stock options will vest 116 on a quarterly basis over four years, subject to such employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan (the "Plan").

The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea's board of directors on November 17, 2023.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn , X and Facebook .

Contact :
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BMEA:US
The Conversation (0)
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase III clinical trials of the Company's investigational covalent menin... Keep Reading...
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on June 1, 2024, the... Keep Reading...
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of... Keep Reading...
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of... Keep Reading...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the... Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - ANK

Canadian Investment Regulatory Organization Trade Resumption - ANK

Trading resumes in: Company: Angkor Resources Corp. TSX-Venture Symbol: ANK All Issues: Yes Resumption (ET): 11:15 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly... Keep Reading...
Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia

Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia

(TheNewswire) GRANDE PRAIRIE, ALBERTA TheNewswire - October 6, 2025 - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has reviewed preliminary data from South Bokor Basin from the 2-D seismic... Keep Reading...
Bold Ventures Discovers New Style of Mineralization on Its Wilcorp Property

Bold Ventures Discovers New Style of Mineralization on Its Wilcorp Property

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the "Company" or "Bold") is pleased to announce the discovery of a new style of mineralization on its Wilcorp Property (the "Property") in the Atikokan area in Ontario, consisting of significant Au-Ag-Cu mineralization from sulphide-quartz stringers in... Keep Reading...
Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units

Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ finlay minerals ltd. (TSXV: FYL,OTC:FYMNF) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the " Private Placement ") consisting of the... Keep Reading...
Quetzal Announces Conditional Acceptance of Reverse Takeover And Filing Statement

Quetzal Announces Conditional Acceptance of Reverse Takeover And Filing Statement

Quetzal Copper Corp. (TSXV: Q,OTC:QTZCF) ("Quetzal") is pleased to announce that it has received conditional acceptance from the TSX Venture Exchange (the "Exchange") for its previously announced reverse takeover transaction (the "Transaction") with Silverco Mining Corp. ("Silverco") (see news... Keep Reading...
Questcorp Mining Provides Update on Private Placement

Questcorp Mining Provides Update on Private Placement

Questcorp Mining Inc. (CSE: QQQ,OTC:QQCMF) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") announces that it has revised the terms of its previously announced non-brokered private placement (the "Offering"). The Company will now offer up to 7,500,000 units (each, an "AI Unit") at a... Keep Reading...

Latest Press Releases

Related News